Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC

OBJECTIVE: To evaluate treatment response, survival, and the associations between KRAS mutation status and tumour expression levels of BRCA1, TYMS and SRC retrospectively in a cohort of patients with non-small cell lung cancer (NSCLC), treated exclusively with conjunctive platinum-based doublet chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Hongxuan, Dai, Yun, Zhu, Liqun, Wang, Chun, Fei, Xiaodong, Pan, Qin, Chen, Juxiang, Shi, Xianqing, Yang, Yanfeng, Tao, Xiaoxing, Shi, Pinghuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536563/
https://www.ncbi.nlm.nih.gov/pubmed/26740498
http://dx.doi.org/10.1177/0300060515607383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536563/
https://www.ncbi.nlm.nih.gov/pubmed/26740498
http://dx.doi.org/10.1177/0300060515607383

Ejemplares similares